Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

826
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
826
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

952
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
952
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Amyloid Fibrils03:03

Amyloid Fibrils

5.2K
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early anthracycline cardiotoxicity in adolescents and young adults with sarcoma: a prospective echocardiographic study.

ESC heart failure·2026
Same author

Targeted autonomic testing for radiation‑induced baroreflex failure in head and neck cancer survivors: index case and early program experience.

Cardio-oncology (London, England)·2026
Same author

Midodrine to facilitate cardioprotective therapy in hypotensive HER2-positive breast cancer patients with cancer-therapy-related cardiac dysfunction-multicenter case experience.

Cardio-oncology (London, England)·2026
Same author

Imaging of Myocardial Carcinoid Metastasis.

JACC. Case reports·2026
Same author

Correction to: 2025 ACC/AHA/ASE/ASNC/SCCT/SCMR Advanced Training Statement on Advanced Cardiovascular Imaging: A Report of the ACC Competency Management Committee.

Circulation. Cardiovascular imaging·2026
Same author

Does Height Influence the Effectiveness of Beta-Blocker Therapy after Myocardial Infarction?

Cardiology·2026

Related Experiment Video

Updated: May 4, 2026

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

9.9K

Cardiac amyloidosis.

Syed Wamique Yusuf1, Amirreza Solhpour, Jose Banchs

  • 1Department of Cardiology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 1451, Houston, TX 77030, USA.

Expert Review of Cardiovascular Therapy
|January 7, 2014
PubMed
Summary
This summary is machine-generated.

Cardiac amyloidosis involves protein buildup in the heart. This review covers its symptoms, diagnosis, and treatment options for better patient outcomes.

More Related Videos

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

7.2K
Isolation and Physiological Analysis of Mouse Cardiomyocytes
11:02

Isolation and Physiological Analysis of Mouse Cardiomyocytes

Published on: September 7, 2014

22.9K

Related Experiment Videos

Last Updated: May 4, 2026

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

9.9K
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

7.2K
Isolation and Physiological Analysis of Mouse Cardiomyocytes
11:02

Isolation and Physiological Analysis of Mouse Cardiomyocytes

Published on: September 7, 2014

22.9K

Area of Science:

  • Cardiology
  • Pathology
  • Internal Medicine

Background:

  • Amyloidosis is defined by extracellular deposition of insoluble fibrillar proteins.
  • These deposits can occur in various tissues and organs, notably the heart.
  • Cardiac involvement significantly impacts patient prognosis and management.

Purpose of the Study:

  • To review the clinical manifestations of cardiac amyloidosis.
  • To summarize current diagnostic strategies for cardiac amyloidosis.
  • To outline available treatment approaches for cardiac amyloidosis.

Main Methods:

  • Literature review of existing studies on cardiac amyloidosis.
  • Synthesis of information on clinical presentation.
  • Compilation of diagnostic criteria and therapeutic interventions.

Main Results:

  • Cardiac amyloidosis presents with diverse clinical symptoms, often mimicking other heart conditions.
  • Early and accurate diagnosis is crucial for effective management.
  • Treatment strategies vary based on amyloid type and disease stage.

Conclusions:

  • Cardiac amyloidosis is a progressive condition requiring a multidisciplinary approach.
  • Timely diagnosis and tailored treatment can improve cardiac function and survival.
  • Further research is needed to develop novel therapeutic targets.